Otis Worldwide Corp (OTIS) Stock Price Today
Aura AI Summary
Key Stats
- $26.08BMarket Cap
- 12,735,044Volume
- IndustrialsSector
- $93.6252W High
- $67.8952W Low
- 65 DaysTypical Hold Time
- $34.12BEnterprise Value
- 2.57%Div Yield
- -Trading Activity
Track Otis Worldwide Corp (OTIS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Otis Worldwide Corp has traded between a low of $66.86 and a high of $93.62, highlighting its annual price range. Buy and sell Otis Worldwide Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Most Recent News
Equitable Holdings directors sell shares amid mixed institutional holdings changes
Two directors of Equitable Holdings sold shares recently, with Bertram L. Scott selling 2,780 shares and Craig C. MacKay selling 2,000 shares. Meanwhile, institutional investors showed mixed activity: Engineers Gate Manager LP drastically cut its hol...

Greenland mining and chip ETFs soar on new security deal and AI optimism
Shares of Greenland-linked mining companies surged following a new U.S.-Denmark-Greenland security agreement that boosted investor interest in Greenland's mineral resources. Greenland Mines Ltd. jumped over 229%, while Critical Metals Corp. rose near...

Biotech stocks and leveraged ETFs lead market declines amid volatile trading and clinical news.
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.